Literature DB >> 22336247

Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity.

Koji Ochiai1, Satoshi Takita, Tomohiko Eiraku, Akihiko Kojima, Kazuhiko Iwase, Tetsuya Kishi, Kazunori Fukuchi, Tokutaro Yasue, David R Adams, Robert W Allcock, Zhong Jiang, Yasushi Kohno.   

Abstract

(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. A survey of potential bicyclic heteroaromatic replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2-(trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin-5-yl analogues as dual PDE3/4-inhibitory compounds that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22336247     DOI: 10.1016/j.bmc.2012.01.033

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis.

Authors:  Lin Ye; Yongning Jia; K E Ji; Andrew J Sanders; Kan Xue; Jiafu Ji; Malcolm D Mason; Wen G Jiang
Journal:  Oncol Lett       Date:  2015-07-06       Impact factor: 2.967

Review 2.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

3.  Crystal structure and Hirshfeld surface analysis of ethyl 2-[5-(3-chloro-benz-yl)-6-oxo-3-phenyl-1,6-di-hydro-pyridazin-1-yl]acetate.

Authors:  Fouad El Kalai; Cemile Baydere; Said Daoui; Rafik Saddik; Necmi Dege; Khalid Karrouchi; Noureddine Benchat
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2019-05-24

4.  Pharmacophore modeling, 3D-QSAR, and docking study of pyrozolo[1,5-a]pyridine/4,4-dimethylpyrazolone analogues as PDE4 selective inhibitors.

Authors:  Naga Srinivas Tripuraneni; Mohammed Afzal Azam
Journal:  J Mol Model       Date:  2015-10-26       Impact factor: 1.810

5.  Intercepting the Breslow intermediate via Claisen rearrangement: synthesis of complex tertiary alcohols without organometallic reagents.

Authors:  Sefat Alwarsh; Kolawole Ayinuola; Silvana S Dormi; Matthias C McIntosh
Journal:  Org Lett       Date:  2012-12-05       Impact factor: 6.005

Review 6.  Selective Phosphodiesterase 4B Inhibitors: A Review.

Authors:  Mohammed Afzal Azam; Naga Srinivas Tripuraneni
Journal:  Sci Pharm       Date:  2014-06-10

Review 7.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12

8.  Docking and quantitative structure-activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors.

Authors:  Camila Muñoz-Gutiérrez; Daniela Cáceres-Rojas; Francisco Adasme-Carreño; Iván Palomo; Eduardo Fuentes; Julio Caballero
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

9.  Synthesis of Some New Pyridazine Derivatives for Anti-HAV Evaluation.

Authors:  Eman M Flefel; Waled A Tantawy; Walaa I El-Sofany; Mahmoud El-Shahat; Ahmed A El-Sayed; Dina N Abd-Elshafy
Journal:  Molecules       Date:  2017-01-17       Impact factor: 4.411

Review 10.  A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool.

Authors:  Nahid Eskandari; Omid Mirmosayyeb; Gazaleh Bordbari; Reza Bastan; Zahra Yousefi; Alireza Andalib
Journal:  J Res Pharm Pract       Date:  2015 Oct-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.